Argo Gr Intl Hldgs Azioni (NYSE: ARGOpA) prezzo delle azioni, notizie, grafici, ricerca sulle azioni, profilo.

Argo Gr Intl Hldgs (NYSE:ARGOpA) Azioni Citazioni e riassunti delle notizie

Argo Group International

Argo Group International Holdings Inc is a property and casualty insurance company. The company has three reportable segments: Casualty Lines, which includes Argo Construction, Argo Environmental, Argo Casualty, Rockwood, Bermuda Casualty, and Bermuda Insurance and Europe; Specialty Lines, which includes Specialty Programs and Fronting, Colony Specialty Garage, Argo Inland Marine, and Bermuda Property; Run-off Lines, which include Liability and surety policies. The company generates the majority of its revenue from the Casualty lines segment. Geographically, the company generates the majority of its revenue from the United States.

FXDFR PRF PERPETUAL USD 25 - 1/1,000TH INT Ser A

Argo Group International Holdings, Inc. Depositary Shares, Each Representing a 1/1,000th Interest in a 7.00% Resettable Fixed Rate Preference Share, Series A

Argo Group International Holdings Inc

BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) reported quarterly sales of $145.53 million which beat the analyst consensus estimate of $126.87 million by 14.71 percent. This is a 56.89 percent increase over sales of $92.76 million the same period last year.

Earnings

Earnings Beats

News

BCRX

BioCryst Pharma Q1 Sales $145.53M Beat $126.87M Estimate

Telsey Advisory Group analyst Sarang Vora maintains Vital Farms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VITL#NASDAQ">VITL</a>) with a Outperform and maintains $52 price target.

Price Target

Analyst Ratings

VITL

Telsey Advisory Group Maintains Outperform on Vital Farms, Maintains $52 Price Target

iRadimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRMD#NASDAQ">IRMD</a>) is looking for Q2 Adj EPS of $0.41-$0.44 vs $0.43 analyst estimate. sees sales of $19.700 million-$19.900 million vs $19.81 million analyst estimate.

Guidance

IRMD

iRadimed Sees Q2 Adj EPS $0.41-$0.44 vs $0.43 Est; Sees Sales $19.700M-$19.900M vs $19.81M Est

Rafael Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RFL#NYSE">RFL</a>, NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RFL#NYSE">RFL</a>) today announced revised subscription rights in connection with its previously announced rights offering.
Holders of record as of May 9, 2025 (the "Record Date") will be eligible to participate in the rights offering. To be considered a Holder of record on the Record Date, prospective Holders must complete open market purchases by May 8, 2025.
Under the proposed rights offering, Rafael Holdings intends to distribute one (1) non-transferable subscription right for each share of Class B Common Stock or Class A Common Stock or share of Class B Common Stock purchasable on exercise of Public Warrants, in each case, held as of the Record Date. Each subscription right will entitle the Holder to purchase 0.603 of a share of Class B Common Stock at a subscription price of $1.28 per share. Subscription rights may only be exercised in whole numbers, and fractional shares will not be issued. The number of shares that may be purchased by each holder of subscription rights will be rounded down to the nearest whole number.
 &nbsp;

Rafael Holdings Revises Subscription Rights Following Prior $25M Rights Offering To Support Development And Potential Launch Of Trappsol Cyclo

iRadimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRMD#NASDAQ">IRMD</a>) affirms FY2025 GAAP EPS guidance from $1.55-$1.65 to $1.55-$1.65 vs $1.64 analyst estimate..

iRadimed Affirms FY2025 GAAP EPS Guidance of $1.55-$1.65 vs $1.64 Est

HC Wainwright &amp; Co. analyst Yi Chen reiterates Tourmaline Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRML#NASDAQ">TRML</a>) with a Buy and maintains $50 price target.

Reiteration

TRML

HC Wainwright & Co. Reiterates Buy on Tourmaline Bio, Maintains $50 Price Target

iRadimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRMD#NASDAQ">IRMD</a>) is looking for Q2 GAAP EPS of $0.37-$0.40 vs $0.41 analyst estimate..

iRadimed Sees Q2 GAAP EPS $0.37-$0.40 vs $0.41 Est

iRadimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRMD#NASDAQ">IRMD</a>) affirms FY2025 Adj EPS guidance from $1.71-$1.81 to $1.71-$1.81 vs $1.75 analyst estimate. Affirms FY2025 sales outlook from $78.00 million-$82.00 million to $78.00 million-$82.00 million vs $79.41 million estimate.

iRadimed Affirms FY2025 Adj EPS Guidance of $1.71-$1.81 vs $1.75 Est; Affirms FY2025 Sales Guidance of $78.00M-$82.00M vs $79.41M Est

Telsey Advisory Group analyst Dana Telsey maintains FIGS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIGS#NYSE">FIGS</a>) with a Market Perform and lowers the price target from $7 to $5.

FIGS

Telsey Advisory Group Maintains Market Perform on FIGS, Lowers Price Target to $5

<ul>
<li>MaGic trial exceeded enrollment target of 60 patients</li>
<li>Top-line results anticipated this September will be the first of three DNTH103 catalysts by YE'26</li>
<li>Building a neuromuscular franchise with DNTH103 in gMG, CIDP and MMN with a potential&nbsp;best-in-class, potent classical pathway inhibitor intended as a self-administered&nbsp;autoinjector dosed once every two weeks</li>
</ul>

DNTH

Dianthus Completes Enrollment In Phase 2 MaGic Trial Of DNTH103 For gMG, Top-Line Results Expected September

Telsey Advisory Group analyst Joseph Feldman maintains Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) with a Outperform and maintains $1100 price target.

COST

Telsey Advisory Group Maintains Outperform on Costco Wholesale, Maintains $1100 Price Target

Needham analyst Laura Martin maintains FuboTV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUBO#NYSE">FUBO</a>) with a Buy and lowers the price target from $3.35 to $3.

FUBO

Needham Maintains Buy on FuboTV, Lowers Price Target to $3

Sunoco LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUN#NYSE">SUN</a>) ("Sunoco" or the "Partnership") and Parkland Corporation (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PKI#TSX">PKI</a>) ("Parkland") announced today that the parties have entered into a definitive agreement whereby Sunoco will acquire all outstanding shares of Parkland in a cash and equity transaction valued at approximately $9.1 billion, including assumed debt. &nbsp;
&nbsp;
As part of the transaction, Sunoco intends to form a new publicly-traded Delaware limited liability company named SUNCorp, LLC ("SUNCorp"). SUNCorp will hold limited partnership units of Sunoco that are economically equivalent to Sunoco's publicly-traded common units on the basis of one Sunoco common unit for each outstanding SUNCorp unit.&nbsp;This new publicly-traded entity will be treated as a corporation for tax purposes. For a period of two years following closing of the transaction, Sunoco will ensure that SUNCorp unitholders will receive the same dividend equivalent as the distribution to Sunoco unitholders.
Transaction Details
Under the terms of the agreement, Parkland shareholders will receive 0.295 SUNCorp units and C$19.80 for each Parkland share, implying a 25% premium based on the 7-day VWAP's of both Parkland and Sunoco as of May 2, 2025. Parkland shareholders can elect, in the alternative, to receive C$44.00 per Parkland share in cash or 0.536 SUNCorp units for each Parkland share, subject to proration to ensure that the aggregate consideration payable in connection with the transaction does not exceed C$19.80 in cash per Parkland share outstanding as of immediately before close and 0.295 SUNCorp units per Parkland share outstanding as of immediately before close.
Sunoco has secured a $2.65 billion 364-day bridge term loan for the proposed cash consideration.
The transaction has been unanimously approved by the board of directors of both companies and is expected to close in the second half of 2025 upon the satisfaction of closing conditions, including approval by Parkland's shareholders and customary regulatory and stock exchange listing approvals.

TSX:PKI

Sunoco to Acquire Parkland Corporation in $9.1B Cash and Equity Deal

RIME

Algorhythm's Subsidiary Announced The Acquisition Of 9,999 Of The 10,000 Issued And Outstanding Equity Shares Of Semicab India In Exchange Of A $1.75M Promissory Note And 119,742 Shares Of Its Common Stock

Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.29) by 31.03 percent. This is a 35.71 percent decrease over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $10.70 million which missed the analyst consensus estimate of $16.83 million by 36.44 percent. This is a 27.59 percent decrease over sales of $14.77 million the same period last year.

Earnings Misses

OCUL

Ocular Therapeutix Q1 EPS $(0.38) Misses $(0.29) Estimate, Sales $10.70M Miss $16.83M Estimate

Stanford-led study included over 2,100 Signatera samples from over 200 sarcoma patients, with overall sensitivity of 89% and specificity of 100%
Leiomyosarcoma, the most common subtype in the cohort, demonstrated sensitivity of 93% and specificity of 100%

NTRA

Natera's Signatera Shows 93% Sensitivity In Leiomyosarcoma, Most Common Sarcoma Subtype In Study

Demonstrated Dose Dependent Effect in EAU
Presented in a podium presentation at The Association for Research in Vision and Ophthalmology (ARVO) 2025 annual meeting
PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) today announced preclinical data on the use of Purified Cortrophin&#xAE; Gel (repository corticotropin injection USP) (Cortrophin Gel) in an EAU mouse model.
"In a preclinical model of autoimmune uveitis, Cortrophin Gel reduced levels of inflammatory molecules without stimulating an adverse immune response," said Mary Pao, MD, PhD, Chief Medical Officer of Rare Disease at ANI. "The results further support our understanding of Cortrophin Gel's mechanism of action."
An experimental autoimmune uveitis (EAU) mouse model was used to determine the impact of four doses (4, 40, 160 or 400 U/kg) of repository corticotrophin injection (RCI, an equivalent to Cortrophin Gel in this model). The results showed a significant dose-dependent effect on the suppression of EAU at all doses, with the greatest suppression of EAU at the 400 U/kg dose. RCI also significantly suppressed the production of cytokines implicated in inflammation and immune system activation. Additionally, 400 U/kg Purified Cortrophin Gel treatment suppressed retinal damage caused by EAU, similar to α-MSH treatment, compared to placebo.
"The data presentation at ARVO is part of ANI's broader commitment to clinical research for our products and, specific to Cortrophin Gel, we are committed to building on the scientific evidence and clinical data supporting its mechanism of action and clinical use," said Nikhil Lalwani, President and Chief Executive Officer at ANI.

Biotech

General

ANIP

ANI Pharmaceuticals Announces Presentation Of Preclinical Data On Use Of Purified Cortrophin Gel In An Experimental Autoimmune Uveitis Mouse Model

Telsey Advisory Group analyst Dana Telsey maintains Zevia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZVIA#NYSE">ZVIA</a>) with a Market Perform and maintains $3 price target.

ZVIA

Telsey Advisory Group Maintains Market Perform on Zevia, Maintains $3 Price Target

KMDA

Kamada Launches Post-Marketing Research Program For CYTOGAM

Pershing Square to Support HHH's Strategic Expansion Through Investment, Advisory, and Other Resources
HHH Will Operate as a Diversified Holding Company Seeking to Acquire Controlling Interests in High-Quality, Durable Growth Public and Private Companies
Howard Hughes Corporation, HHH's Real Estate Development Business and Principal Subsidiary,&nbsp;Will Continue as the Nation's Leading Community Builder
Pershing Square's Primary Purchase of HHH Stock for $100.00 per Share&nbsp;Represents a 48% Premium to Friday's Closing Price
Pershing Square Will Now Own 46.9% of the Company
Pershing Square's Investment Materially Improves Howard Hughes' Credit Profile and Strategic and Financial Flexibility
THE WOODLANDS, Texas and NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Howard Hughes Holdings Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HHH#NYSE">HHH</a>) (the "Company," "Howard Hughes" or "HHH") and Pershing Square Holdco, L.P. and its wholly owned subsidiary, Pershing Square Capital Management, L.P. (collectively, "Holdco" or "Pershing Square"), today announced an agreement pursuant to which Pershing Square will today invest $900 million to acquire 9,000,000 newly issued shares of HHH. Pershing Square's investment will enable HHH to become a diversified holding company by acquiring controlling stakes in high-quality, durable growth public and private operating companies while continuing to invest in and grow the Company's core real estate development and Master Planned Communities business.
Pershing Square's acquisition of $900 million of newly issued shares of HHH common stock for $100.00 per share represents a premium of 48% to HHH's closing share price on Friday, May 2, 2025. Pershing Square will now own 46.9% of HHH shares outstanding. Pershing Square has generally agreed to limit its voting power to 40% and its beneficial ownership to 47%.
Pershing Square's Chairman and Chief Executive Officer, Bill Ackman, has been named the Executive Chairman of the HHH Board of Directors. Ryan Israel, Pershing Square's Chief Investment Officer, will become HHH's Chief Investment Officer, a new senior leadership role at the Company. The HHH leadership team, led by CEO David O'Reilly, will remain unchanged with expanded roles and responsibilities. HHH's other employees will remain unchanged.
As part of the transaction, the entire Pershing Square organization will now be available to HHH to support the Company's transformation by providing investment, advisory, and other ancillary services, including corporate development, transaction execution, and capital markets assistance. Pershing Square will also assist HHH in identifying and hedging macro-related risks.
Pershing Square Holdco is owned 90% by Pershing Square principals and 10% by strategic investors. Holdco's $900 million investment represents a ‘look-through' cash investment by Pershing Square principals of $810 million. When combined with the Pershing Square funds' existing ownership, this represents a total look-through investment in HHH of $1.2 billion by Pershing Square's principals.
HHH will pay Pershing Square a quarterly base fee of $3.75 million and a quarterly management fee equal to 0.375% of the increase in HHH's equity market capitalization above the Reference Market Cap of the Company. &nbsp;The Reference Market Cap is determined by multiplying the post-transaction share count of 59,393,938 (the "Reference Share Count") by the Reference Market Price of $66.1453, which is adjusted annually for inflation, subject to equitable adjustment for stock splits, reclassifications or similar capital changes. The Reference Share Count does not change in the event the Company issues additional shares to raise equity, to acquire a company for stock, or to provide equity compensation to employees. As a result, the management fee will not increase due to share issuances. It will only increase if the Company's share price compounds at a rate in excess of inflation.&nbsp;
HHH will not pay any additional fees, cash compensation, or equity incentives to Pershing Square or its principals or employees.
"This transaction is the result of a rigorous process overseen by HHH's Special Committee, which included evaluation of each of Pershing Square's proposals, feedback from HHH stockholders and robust negotiations with Pershing Square's principals to reach a mutually favorable outcome," said Scot Sellers, Chairman of the Special Committee. Mr. Sellers continued, "We believe this agreement not only reflects the value that HHH has created in recent years, but it also positions the Company to transform its strategy, with enhanced value creation opportunities and upside potential, while improving its credit profile. With Bill's and Ryan's long-term track record of investment success, along with the expertise and support of the entire Pershing Square team, HHH will seek to acquire controlling interests in high-quality, cash-flow-generative public and private companies for the benefit of all HHH stockholders. We are confident the Company is now even better positioned to deliver long-term, sustainable value for our stockholders."
"I am delighted to return to HHH as its Executive Chairman with the addition of Ryan to assist in transforming the Company to a diversified holding company," said Bill Ackman. "HHH has built substantial value for shareholders in recent years that has largely gone unrecognized due to the high cost of capital that the market assigns to the Company in light of its pure-play exposure to real estate development and community creation. We believe that HHH is a superb platform to build a faster-growing, high-returning holding company that will acquire control of companies that meet Pershing Square's criteria for business quality and durable growth. We are looking forward to working with David and the rest of the HHH team in creating long-term value."

Pershing Square Announces $900M Investment To Acquire 9M Newly Issued Shares Of Howard Hughes Holdings At $100 Per Share

Argo Gr Intl Hldgs

Learn About Cryptocurrency

acf/sidebar-related-posts

Learn about this leading blockchain platform that supports decentralized applications and smart contracts.

What is Ethereum?

Earning interest on your Ethereum is a great way to grow your cryptocurrency holdings. Find out how to earn interest on your Ethereum in 4 easy steps.

How to Earn Interest on Ethereum

Discover the 10 best cryptocurrencies to invest in for January 2025. Stay ahead in the crypto market with our expert insights and analysis! Learn more now!

10 Best Cryptocurrencies to Invest In for May 2025

10 Best Cryptocurrencies to Invest in for January 2025

Discover the best altcoins to invest in for high potential returns. Our top altcoin picks include Ethereum, Solana, Ripple, Dogecoin, Toncoin.

Top 10 Best Altcoins • Benzinga Crypto

10 Best Altcoins in November 2024

Top Cryptocurrency News

acf/news-feed

Aperto	-
Chiuso	-
Volume / Media	0 / 23.82K
Intervallo giornaliero	- - -
Intervallo a 52 settimane	24.14 - 25.49
Capitalizzazione di mercato	-
Rapporto P/E	-
Rendimento del dividendo	6.97%
Exchange	NYSE
RSI	0
Vendite allo scoperto	-
Periodo di copertura	-

Aperto	-
Chiuso	-
Volume / Media	0 / 23.82K
Intervallo giornaliero	- - -
Intervallo a 52 settimane	24.14 - 25.49
Capitalizzazione di mercato	-
Rapporto P/E	-
Rendimento del dividendo	6.97%
Exchange	NYSE
RSI	0
Vendite allo scoperto	-
Periodo di copertura	-

Comments

Argo Gr Intl Hldgs

Argo Gr Intl Hldgs (ARGOpA) Previsione

Argo Gr Intl Hldgs (NYSE:ARGOpA) Azioni Citazioni e riassunti delle notizie

Notizie recenti

Dati finanziari

Confronta

FAQ

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Nome

Ricavi Variazioni
Lordo Variazioni
EBITDA Variazioni
EBIT Variazioni
Utili Variazioni